Critical appraisal of the Source CPGs by the Appraisal of Guidelines for Research & Evaluation II (AGREE II) Instrument.
| CPGs AGREE-II domains scores (%) | Texas 2009 | NICE 2012 | NCS 2012 | AES 2016 |
|---|---|---|---|---|
| Domain 1: Scope & Purpose | 92 | 100 | 78 | 100 |
| Domain 2: Stakeholder Involvement | 47 | 100 | 41 | 44 |
| Domain 3: Rigour of Development | 56 | 98 | 68 | 69 |
| Domain 4: Clarity & Presentation | 100 | 97 | 80 | 92 |
| Domain 5: Applicability | 48 | 85 | 10 | 21 |
| Domain 6: Editorial Independence | 50 | 88 | 19 | 38 |
| Overall Assessment (%) | 85 | 100 | 57 | 75 |
| Recommendation for CPG use | Yes - 1, Yes with modifications - 1, No - 0 | Yes - 1, Yes with modifications - 1, No - 0 | Yes - 1, Yes with modifications - 0, No - 1 | Yes - 1, Yes with modifications - 1, No - 0 |
The overall assessment and decision of the CPG Adaptation working group, based on the AGREE-II domain scores, was to adapt the NICE CPG and exclude the Texas, NCS, and AES CPGs. CPGs: Clinical Practice Guidelines, AGREE: Appraisal of Guidelines for Research and Evaluation, Texas: Texas Children’s Hospital Evidence-Based Outcomes Center, NICE: National Institute for Health and Care Excellence, NCS: Neurocritical Care Society, AES: American Epilepsy Society